2006
DOI: 10.1021/op0601621
|View full text |Cite
|
Sign up to set email alerts
|

Process Development and Scale-up of AG035029

Abstract: A practical process for the synthesis of PPARγ agonist AG035029 was developed which involved six steps along the longest linear path. The process development utilized automated technology and computational chemistry extensively to accelerate the speed of the project in the areas of catalyst screening, reaction optimization, mechanistic studies, and polymorph control.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
15
0

Year Published

2008
2008
2019
2019

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 17 publications
(16 citation statements)
references
References 7 publications
1
15
0
Order By: Relevance
“…The alkylation of methyl 1 H -indazole-3-carboxylate ( 12 ) proceeded regioselectively to favour the formation of 1-substituted 1 H -indazole intermediates as major products, entirely consistent with the known reactivity of indazoles towards nucleophilic substitution [ 56 58 ]. To quantify the regioselectivity of each alkylation method, the isolated yields of the regioisomeric products obtained following alkylation of 12 under each set of conditions for two representative bromoalkanes were determined are shown in Table 1 .…”
Section: Resultssupporting
confidence: 54%
“…The alkylation of methyl 1 H -indazole-3-carboxylate ( 12 ) proceeded regioselectively to favour the formation of 1-substituted 1 H -indazole intermediates as major products, entirely consistent with the known reactivity of indazoles towards nucleophilic substitution [ 56 58 ]. To quantify the regioselectivity of each alkylation method, the isolated yields of the regioisomeric products obtained following alkylation of 12 under each set of conditions for two representative bromoalkanes were determined are shown in Table 1 .…”
Section: Resultssupporting
confidence: 54%
“…Drug doses were chosen for near-maximal insulin-sensitizing effect without nonspecific effects (approximate EC 90 doses) (27,50,54). AG-035029 (22,38) is an experimental PPAR␥-selective ligand obtained from Pfizer, Inc., La Jolla, CA (see also DISCUSSION). Lean control (LC) rats were all fed normal chow.…”
Section: Methodsmentioning
confidence: 99%
“…Platinum on carbon (Pt/C) is oen used for reduction of nitro to amine in a mild condition without affecting other adjacent groups. [28][29][30] Here, Pt/C was also successfully employed to reduce the nitro group under ambient condition using an H 2 balloon without loss of the benzyl group to produce 12 in excellent yield (Scheme 1, vii).…”
Section: Resultsmentioning
confidence: 99%